<?xml version='1.0' encoding='utf-8'?>
<document id="30422319"><sentence text="Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects." /><sentence text="Rolapitant (Varubi) is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced nausea and vomiting" /><sentence text=" Rolapitant is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme" /><sentence text=" Unlike other neurokinin-1 receptor antagonists, rolapitant is neither an inhibitor nor an inducer of CYP3A4 in vitro" /><sentence text=" The objective of this analysis was to examine the pharmacokinetics of rolapitant in healthy subjects and assess drug-drug interactions between rolapitant and midazolam (a CYP3A substrate), ketoconazole (a CYP3A inhibitor), or rifampin (a CYP3A4 inducer)"><entity charOffset="144-154" id="DDI-PubMed.30422319.s5.e0" text="rolapitant" /><entity charOffset="159-168" id="DDI-PubMed.30422319.s5.e1" text="midazolam" /><entity charOffset="190-202" id="DDI-PubMed.30422319.s5.e2" text="ketoconazole" /><entity charOffset="227-235" id="DDI-PubMed.30422319.s5.e3" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.30422319.s5.e0" e2="DDI-PubMed.30422319.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30422319.s5.e0" e2="DDI-PubMed.30422319.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30422319.s5.e0" e2="DDI-PubMed.30422319.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30422319.s5.e0" e2="DDI-PubMed.30422319.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30422319.s5.e1" e2="DDI-PubMed.30422319.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30422319.s5.e1" e2="DDI-PubMed.30422319.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30422319.s5.e1" e2="DDI-PubMed.30422319.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30422319.s5.e2" e2="DDI-PubMed.30422319.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30422319.s5.e2" e2="DDI-PubMed.30422319.s5.e3" /></sentence><sentence text=" Three phase 1, open-label, drug-drug interaction studies were conducted to examine the pharmacokinetic interactions of orally administered rolapitant with midazolam, rolapitant with ketoconazole, and rolapitant with rifampin"><entity charOffset="156-165" id="DDI-PubMed.30422319.s6.e0" text="midazolam" /><entity charOffset="167-177" id="DDI-PubMed.30422319.s6.e1" text="rolapitant" /><entity charOffset="183-195" id="DDI-PubMed.30422319.s6.e2" text="ketoconazole" /><entity charOffset="201-211" id="DDI-PubMed.30422319.s6.e3" text="rolapitant" /><entity charOffset="217-225" id="DDI-PubMed.30422319.s6.e4" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.30422319.s6.e0" e2="DDI-PubMed.30422319.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30422319.s6.e0" e2="DDI-PubMed.30422319.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30422319.s6.e0" e2="DDI-PubMed.30422319.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30422319.s6.e0" e2="DDI-PubMed.30422319.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30422319.s6.e0" e2="DDI-PubMed.30422319.s6.e4" /><pair ddi="false" e1="DDI-PubMed.30422319.s6.e1" e2="DDI-PubMed.30422319.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30422319.s6.e1" e2="DDI-PubMed.30422319.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30422319.s6.e1" e2="DDI-PubMed.30422319.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30422319.s6.e1" e2="DDI-PubMed.30422319.s6.e4" /><pair ddi="false" e1="DDI-PubMed.30422319.s6.e2" e2="DDI-PubMed.30422319.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30422319.s6.e2" e2="DDI-PubMed.30422319.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30422319.s6.e2" e2="DDI-PubMed.30422319.s6.e4" /><pair ddi="false" e1="DDI-PubMed.30422319.s6.e3" e2="DDI-PubMed.30422319.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30422319.s6.e3" e2="DDI-PubMed.30422319.s6.e4" /></sentence><sentence text=" The pharmacokinetic profiles of midazolam and 1-hydroxy midazolam metabolites were essentially unchanged when coadministered with rolapitant, indicating the lack of a clinically relevant inhibition or induction of CYP3A by rolapitant"><entity charOffset="33-42" id="DDI-PubMed.30422319.s7.e0" text="midazolam" /><entity charOffset="47-66" id="DDI-PubMed.30422319.s7.e1" text="1-hydroxy midazolam" /><entity charOffset="131-141" id="DDI-PubMed.30422319.s7.e2" text="rolapitant" /><pair ddi="false" e1="DDI-PubMed.30422319.s7.e0" e2="DDI-PubMed.30422319.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30422319.s7.e0" e2="DDI-PubMed.30422319.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30422319.s7.e0" e2="DDI-PubMed.30422319.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30422319.s7.e1" e2="DDI-PubMed.30422319.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30422319.s7.e1" e2="DDI-PubMed.30422319.s7.e2" /></sentence><sentence text=" Coadministration of ketoconazole with rolapitant had no effects on rolapitant maximum concentration and resulted in an approximately 20% increase in the area under the concentration-time curve of rolapitant, suggesting that strong CYP3A inhibitors have minimal inhibitory effects on rolapitant exposure"><entity charOffset="21-33" id="DDI-PubMed.30422319.s8.e0" text="ketoconazole" /><entity charOffset="39-49" id="DDI-PubMed.30422319.s8.e1" text="rolapitant" /><pair ddi="false" e1="DDI-PubMed.30422319.s8.e0" e2="DDI-PubMed.30422319.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30422319.s8.e0" e2="DDI-PubMed.30422319.s8.e1" /></sentence><sentence text=" Repeated administrations of rifampin appeared to reduce rolapitant exposure, resulting in a 33% decrease in maximum concentration and 87% decrease in area under the concentration-time curve from time zero to infinity"><entity charOffset="29-37" id="DDI-PubMed.30422319.s9.e0" text="rifampin" /></sentence><sentence text=" Coadministration of rolapitant did not affect the exposure of midazolam"><entity charOffset="63-72" id="DDI-PubMed.30422319.s10.e0" text="midazolam" /></sentence><sentence text=" Rifampin coadministration resulted in lower concentrations of rolapitant, and ketoconazole coadministration had no or minimal effects on rolapitant exposure"><entity charOffset="1-9" id="DDI-PubMed.30422319.s11.e0" text="Rifampin" /><entity charOffset="63-73" id="DDI-PubMed.30422319.s11.e1" text="rolapitant" /><entity charOffset="79-91" id="DDI-PubMed.30422319.s11.e2" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.30422319.s11.e0" e2="DDI-PubMed.30422319.s11.e0" /><pair ddi="false" e1="DDI-PubMed.30422319.s11.e0" e2="DDI-PubMed.30422319.s11.e1" /><pair ddi="false" e1="DDI-PubMed.30422319.s11.e0" e2="DDI-PubMed.30422319.s11.e2" /><pair ddi="false" e1="DDI-PubMed.30422319.s11.e1" e2="DDI-PubMed.30422319.s11.e1" /><pair ddi="false" e1="DDI-PubMed.30422319.s11.e1" e2="DDI-PubMed.30422319.s11.e2" /></sentence><sentence text=" Rolapitant was safe and well tolerated when coadministered with ketoconazole, rifampin, or midazolam"><entity charOffset="65-77" id="DDI-PubMed.30422319.s12.e0" text="ketoconazole" /><entity charOffset="79-87" id="DDI-PubMed.30422319.s12.e1" text="rifampin" /><entity charOffset="92-101" id="DDI-PubMed.30422319.s12.e2" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.30422319.s12.e0" e2="DDI-PubMed.30422319.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30422319.s12.e0" e2="DDI-PubMed.30422319.s12.e1" /><pair ddi="false" e1="DDI-PubMed.30422319.s12.e0" e2="DDI-PubMed.30422319.s12.e2" /><pair ddi="false" e1="DDI-PubMed.30422319.s12.e1" e2="DDI-PubMed.30422319.s12.e1" /><pair ddi="false" e1="DDI-PubMed.30422319.s12.e1" e2="DDI-PubMed.30422319.s12.e2" /></sentence><sentence text=" No new safety signals were reported compared with previous studies of rolapitant"><entity charOffset="71-81" id="DDI-PubMed.30422319.s13.e0" text="rolapitant" /></sentence><sentence text="" /></document>